According to the strategic technological framework defined by Biosckin, in 2008 the Research, Development & Innovation (IDI) nucleus, called BioMat&Cell, was created.
The creation of Biosckin’s RDI nucleus allowed the company to develop internal research and development and innovation management skills in the company, through the creation of a structured unit with permanence characteristics and dedicated exclusively to industrial research and experimental development activities in area of Regenerative Medicine and Cell Therapy, areas in which Biosckin intends to be a European reference.
The RDI core is adjusted to the company’s innovation policy in relation to the two areas of intervention. The first area carries out work in the development of new Biomaterials and the second, in the development of Cellular Therapies using stem cells from umbilical cord blood and umbilical cord tissue. Since April 2012, the RDI core has been considering certification by NP 4457.
The elements that are assigned to RDI activities have curricular profiles appropriate to the area of activity of the nucleus, with the team consisting of doctorates and masters.
The company has several connections with Portuguese Universities, protocols and contracts with companies, international collaborations and several research partnerships.
These partnerships allow the formation of a multidisciplinary team in the area of Regenerative Medicine and all are based on formal protocols that are independent of the shareholder structure and that give Biosckin an enormous capacity for technological updating and scientific advancement.